Holen Sie sich die Stockscreener-App
58.48
0.15%
-0.09
Vorhandelsmarkt:
58.51
0.03
+0.05%
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
US$49.54That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results - simplywall.st
10x Genomics, Inc. (TXG) Stock Analysis: Navigating the High Valuation and Market Dynamics - DirectorsTalk Interviews
Is 10x Genomics Inc (TXG) Overvalued After 12.3% Rally? GF Value - GuruFocus
10x Genomics, Inc. (TXG) stock price, news, quote and history - Yahoo Finance UK
10x Genomics (NASDAQ:TXG) Trading Up 7.1%Time to Buy? - MarketBeat
TXG Stock Jumps As Earnings Beat Triggers Analyst Upgrades - StocksToTrade
10X GENOMICS INC : CANACCORD GENUITY RAISES TARGET PRICE TO $60 FROM $50 - Bitget
10x Genomics Stock Jumps As Analysts Hike Price Targets - timothysykes.com
10X Genomics Inc (TXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of 10x Genomics Inc Class A – BMV:TXG - TradingView
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX) - The Globe and Mail
TXG Jumps As 10x Genomics Price Targets Surge After Q2 Beat - timothysykes.com
10X Genomics Inc (TXG) Stock News Today - TradingKey
10x Genomics, Inc. Stock 12‑Month Price Target Raised to $47.23, Implies 4% Upside - TradingView
10x Genomics Q2 Earnings Call Highlights - MarketBeat
10x Genomics stock hits 52-week high at 50.36 USD - Investing.com
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up - finance.yahoo.com
10X GENOMICS, INC. : JEFFERIES RAISES TARGET PRICE TO $53 FROM $40 - moomoo.com
10x Genomics, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
10x Genomics (NASDAQ: TXG) grows consumables, ends Q2 with $502M cash - Stock Titan
10x Genomics, Inc. 2026: Revenue $151.04M, EPS ($0.14) — 10-Q Summary - TradingView
10x Genomics $TXG Shares Sold by Janus Henderson Group PLC - MarketBeat
TXG|10X Genomics Inc|Price:58.260|Chg%:+6.230 - TradingKey
Has 10x Genomics Inc (TXG) Missed Earnings Expectations with Q2 - GuruFocus
10x Genomics (NASDAQ:TXG) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Earnings call transcript: 10x Genomics tops Q2 2026 estimates, shares fall - Investing.com
Transcript : 10x Genomics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
10x Genomics Inc (TXG) Shares Fall 3.9% -- What GF Score of 58 T - GuruFocus
10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations - finance.yahoo.com
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - finance.yahoo.com
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
10x Genomics falls 2% despite beating revenue estimates - Investing.com
10x Genomics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
(TXG) 10x Genomics Now Expects 2026 Revenue Range $610M-$630M, vs. FactSet Est of $613.7M - marketscreener.com
Q2 2026 10X Genomics Inc Earnings Call Transcript - GuruFocus
10x Genomics Q2 2026: Revenue $151.0M, Gross Margin 74%, Raises 2026 Revenue Guide - TradingView
10x Genomics: Q2 Earnings Snapshot - AOL.com
Earnings Flash (TXG) 10x Genomics, Inc. Reports Q2 Revenue $151.0M, vs. FactSet Est of $146.7M - marketscreener.com
10x Genomics (NASDAQ: TXG) swings to Q2 loss but lifts 2026 revenue guide - Stock Titan
10x Genomics Reports Second Quarter 2026 Financial Results - marketscreener.com
10x Genomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
10X Genomics faces earnings test as revenue expected to decline By Investing.com - Investing.com Nigeria
10x Sued Over Spatial Genomics Patents by Caltech, Licensee (1) - Bloomberg Law News
10x Genomics (TXG) 10K Form and Latest SEC Filings 2026 - MarketBeat
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
10x Genomics, Inc. (TXG) - DirectorsTalk Interviews
58,083 Shares in 10x Genomics $TXG Acquired by Edgestream Partners L.P. - MarketBeat
Lazard Asset Management LLC Sells 45,761 Shares of 10x Genomics $TXG - MarketBeat
10x Genomics (TXG) Teams Up With Lausanne Hospital To Push Cancer Diagnostics Forward - finance.yahoo.com
Enterprise value to revenue forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10x Genomics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
10x Genomics $TXG Shares Sold by Renaissance Technologies LLC - MarketBeat
10x Genomics, Lausanne University Hospital Partner for Cancer Biomarker Research - Contract Pharma
Principal Financial Group Inc. Sells 22,177 Shares of 10x Genomics $TXG - MarketBeat
10x Genomics, Inc. (TXG) Stock Analysis: Navigating a Pioneering Path in Health Information Services - DirectorsTalk Interviews
TXG|10X Genomics Inc|Price:47.435|Chg%:+0.165 - TradingKey
10X Genomics Inc (TXG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TXG|10X Genomics Inc|Price:46.270|Chg%:-1.790 - TradingKey
10x Genomics, Inc. Revenue Breakdown – NASDAQ:TXG - TradingView
10x Genomics, Inc. (TXG) Interactive Stock Chart - Yahoo! Finance Canada
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know - Yahoo Finance
10X Genomics2026 Funding Rounds & List of Investors - Tracxn
10x Genomics stock hits 52-week high at 46.35 USD By Investing.com - Investing.com South Africa
10x Genomics stock hits 52-week high at 46.35 USD - Investing.com UK
How 10x Genomics Inc. (TXG) Affects Rotational Strategy Timing - Stock Traders Daily
10x Genomics (NASDAQ:TXG) Sets New 12-Month HighWhat's Next? - MarketBeat
Bioinformatics Collaboration and Licensing Deals 2019-2026 | Compare Upfronts, Milestones, and Royalties for 1,230+ Deals - GlobeNewswire Inc.
10X Genomics Inc (TXG) Institutional Confidence - TradingKey
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026 - BioSpace
2.80%
1.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):